Blog Category

admin

Biophytis has filed with the EMA for authorization to initiate SARA-31 phase 3 study in sarcopenia

, , ,

/

15 May 2023

Successful capital increase for Biophytis with €2.3 million raised

,

/

11 May 2023

Biophytis launches a round of fundraising for approximately 2 million euros

,

/

10 May 2023

Biophytis has requested a pre-submission meeting with the EMA for the Marketing Authorisation of Sarconeos (BIO101) for the treatment of COVID-19

,

/

9 May 2023

Biophytis strengthens its management team

,

/

2 May 2023

Biophytis announces receipt of Nasdaq Notice

,

/

28 April 2023

Biophytis regains compliance with NASDAQ minimum bid price requirement

,

/

19 April 2023

Biophytis Announces 2022 Financial Results and 2023 Perspectives

,

/

18 April 2023

The Combined General Meeting will be held on second call on April 17, 2023

,

/

31 March 2023

Biophytis presented Sarconeos (BIO101) as a possible treatment candidate for long COVID after hospitalization during the 13th annual International Conference on Frailty and Sarcopenia Research (ICFSR)

, , ,

/

27 March 2023

Biophytis to Present Sarconeos’ (BIO101) Development as a Drug Candidate in Rare Neuromuscular Diseases at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

, , ,

/

20 March 2023

Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program

,

/

17 March 2023